Dr. Xieqiao Yan is a rising young expert in the field of genitourinary malignancies in China. He has long been dedicated to the clinical management and research of renal cell carcinoma, urothelial carcinoma, prostate cancer, and other genitourinary cancers. He previously conducted visiting studies at the Melanoma Institute Australia (MIA), gaining international exposure and solid evidence-based medical training.
Dr. Yan has extensive experience in chemotherapy, targeted therapy, immunotherapy, and combination treatment strategies for genitourinary cancers. He has accumulated significant expertise particularly in the systemic treatment of advanced malignancies. He has led and participated in multiple national key research programs and has served as a Sub-I in numerous phase I–III clinical trials of genitourinary tumors. His research focuses on tumor pathogenesis, molecular biomarkers, and the development of novel therapeutic strategies. In addition, Dr. Yan has been actively involved in drafting and updating several authoritative national clinical guidelines for genitourinary cancers, contributing to the development and promotion of standardized cancer care in China.
